Marks Electrical Share Discussion Threads

[brummy_git] 11/4/2022 07:37

Fabulous Q4'22 results from Marks Electrical today.

Find out all the details & investor interpretation here.

www.linkedin.com/posts/paul-hill-a5994116_mrk-mrk-activity-6919170931856674817-xsOy?utm_source=linkedin_share&utm_medium=member_desktop_web

[leoinvestoruk] 14/2/2022 17:30

Mark Smithson (Founder / CEO) and Josh Egan (CFO) will be live and in person at the Small Caps Live Midlands investor meet on the 23rd March for a presentation plus Q&A.

Details and registration here:

[chinahere] 22/1/2022 12:38

I was all ready to buy some on Monday and in anticipation I started reading the IPO documents.

What I didn't at first realise was that 90% of MRK electricals come from the CIH/Euronics group. CIH may be mutually owned but it appears to want to take more control:

"Announcing his intention to make CIH/Euronics “the dominant force in electrical retailing”, Scogings said: “No longer are we happy to take a back seat and be an afterthought. Over the next few weeks, and years, we will rise further to be the dominant force in electrical retailing......"



I had assumed that MRK was directly purchasing from suppliers.

Anyone agree that this CIH connection is a risk?

[brummy_git] 22/1/2022 04:03

MRK (starts 39:50) discussed by Paul Hill & Justin Waite of Vox markets here

www.youtube.com/watch?v=gA_6tDwJA5k

[brummy_git] 22/1/2022 03:54

MRK discussed by Jamie Constable of Singer Capital markets & Paul Hill here (starts 33:05)

www.linkedin.com/posts/paul-hill-a5994116_singer-capital-markets-macro-update-january-activity-6890241940429123584-VgtD

[brummy_git] 10/1/2022 07:12

Fabulous trading update from recently IPO’d Marks Electrical . A fast growing, online retailer of premium household appliances such as cookers, televisions, fridges, freezers & dish-washers.

All the news & commentary here.

www.linkedin.com/posts/paul-hill-a5994116_mrk-mrk-mrk-activity-6886200745473916928-b507

[masurenguy] 02/1/2022 14:09

IPO on 5 November 2021 was @110p, valuing the company @£115.4m

Major Shareholders as at 1st January 2022
Mark Smithson: 75,272,727: 71.7%
Canaccord Genuity Ltd: 5,500,000: 5.2%
Stancroft Trust Ltd: 5,454,545: 5.2%
Octopus Investments Ltd: 4,090,909: 3.9
Top 4 shareholders: 86.0%

On my watchlist - no current position.

[masurenguy] 02/1/2022 11:12

Marks Electrical Group listed on the stockmarket in November. Barring one set of half-year results, we have learned little about it since – except the share price has risen by 10%. The company’s flotation allowed owner and founder Mark Smithson to cash in nearly 30% of his shares at a propitious time. The company sells cookers, refrigerators, washing machines and televisions, and for substantial periods competitors such as Currys and John Lewis had closed their retail stores due to lockdowns. Almost all Marks Electricals sales were made online.

An internet-sales boom coupled with a shortage of supply drove profitability to remarkable levels. So we must be cautious about the firm’s immediate prospects. Although Marks Electrical anticipates revenue growth of 35%-45% in the current financial year, profit margins will fall now that rivals’ stores have reopened. My back-of the-envelope forecast suggests, conservatively, that the shares may be trading on a multiple of 27 times the profit it might earn in 2022.

That is quite a price tag, but over the long term Marks Electrical believes it can increase its market share from 1.5% to 10%. One reason is that it is almost completely unknown, something it plans to change by spending more on advertising. Another is that it is a simpler, more coherent business than its rivals. A focus on premium brands of bulky electricals means the value of each lorry load is high, which justifies the expense of owning its own fleet staffed with trained installers who are incentivised partly by customers’ ratings.

Vehicles are maintained and fuelled at its only warehouse, from which it can deliver next day to nearly all the people of England and Wales. Automated systems keep prices keen without undercutting rivals because it sells itself on service – witness glowing reviews. As customers move their spending online, Marks Electrical may be a better long-term bet than the alternative, bigger but less focused AO World.

[brummy_git] 26/11/2021 15:13

MRK discussed here (13:00)

www.youtube.com/watch?v=4PCSEnaOMA8

[polx] 23/11/2021 08:33

AO. profit warning today.

[brummy_git] 18/11/2021 08:05

If your need a new fridge, freezer, TV or cooker, then look no further than Marks Electrical Group plc. A fast growing, online retailer of household appliances.

In this fascinating interview, CEO, Founder & born entrepreneur Mark Smithson and CFO Josh Egan run through:

a) The company's key USPs
b) What’s driving the strong LFL sales growth?
c) How the industry's supply chain & cost inflation issues have been successfully managed
d) Key highlights from today's interims
e) October's record trading & outlook for FY'22
f) Theoretically how large Marks might become, say in 5 years’ time
g) Future newsflow

“On your Marks, get set, go”

www.youtube.com/watch?v=PfHfwrQz2Mg&t=1s

[brummy_git] 18/11/2021 07:15

Terrific H1 results today (LFL sales up 78% to £37.5m) from Marks Electrical, alongside 'record' October trading & a strong outlook for the rest of H2'22 & beyond.

Find out all the latest news, valuation & commentary here.

www.linkedin.com/posts/paul-hill-a5994116_mrk-mrk-activity-6866995648642772992-zwLr

[ihavelosteverything] 09/11/2021 07:59

5.5 million quid bought by an institution on the first trading day, a very good sign.

A few articles suggest the value of MRK is 135-175 M.




A nice one to keep for years, waiting for the divs too.

[hedgehog 100] 06/11/2021 10:50

Current share price 6th. November 2021: 110.5p
Market capitalisation: £115.97M.


"ABOUT US
For over 30 years, Marks Electrical have been selling the best of appliances and televisions to over a million satisfied customers. Since 1987, we've provided high-quality products at competitive prices and we stand today as an independent elite retailer and member of Euronics. We pride ourselves on our achievements and the accolades we've been honoured to accept, including Best Website at the IER Awards. Further success is our driving force."



"Investment case
In FY21, we had 1.2% market share of a £5.3 billion major domestic appliances market…"



Marks Electrical Grp Placing and Proposed Admission to Trading on AIM
RNS Number : 0417R Marks Electrical Group plc 02 November 2021

"Marks Electrical, a fast growing online electrical retailer, announces its proposed admission to trading on AIM ("Admission") and its successful placing, conditional on Admission, (the "Placing") of 4,545,454 new ordinary shares (the "New Shares") and 22,727,273 existing ordinary shares (the "Sale Shares") of 1 pence each in the capital of the Company (the "Shares") both at a price of 110 pence per Share (the "Placing Price") with institutional and other investors. ...

· Based on the Placing Price, the market capitalisation of the Company will be approximately £115 million on Admission.

· On Admission, the Company will have 104,949,050 Shares in issue and a free float of approximately 25.9 per cent.

· The Placing attracted strong support from high quality institutional investors and was over-subscribed.

· The Placing of 4,545,454 New Shares is expected to raise approximately £2.6 million after deduction of commissions and expenses ("net proceeds").

· The net proceeds will provide the Company with sufficient cash reserves for potential future investments in capacity enhancement, including additional vehicle capacity to continue scaling-up, as well as the costs associated with moving to larger premises when growth has outstripped the capacity of the existing premises and any leasehold improvements that may be necessitated by such a move.

· The Placing of the Sale Shares is expected to raise gross proceeds of £25.0 million for the Selling Shareholder. ..."




05/11/2021 07:00 UK Regulatory (RNS & others) Marks Electrical Group plc Admission to AIM and First Day of Dealings LSE:MRK Marks Electrical Group Plc

"Marks Electrical, a fast growing online electrical retailer, is pleased to announce the admission of its entire issued and to be issued share capital to trading on the AIM market of the London Stock Exchange. Admission will take place and dealings will commence at 8.00 a.m. today under the ticker MRK and ISIN GB00BM8Q5G47.

The Company's Admission Document is available to view on the Company's website at group.markselectrical.co.uk

Mark Smithson, Founder & Chief Executive Officer of Marks Electrical, commented:

"Our admission to AIM is an exciting milestone for Marks Electrical. The successful completion of our IPO represents the beginning of a new chapter as we continue to scale the business and grow our share of the huge online retail market for home appliances.

"I am delighted to welcome our new shareholders and would like to thank them for their support. We look forward to working with them in the years ahead as we build on our strong momentum and push forward with our ambitious growth plans." ...

Marks Electrical sells, delivers, installs and recycles a wide range of household electrical products. The Marks Electrical group was founded in Leicester in 1987 by its Chief Executive Officer, Mark Smithson, and has expanded into a nationwide online retailer, with a strong track record of growth and scaling the business as a result of the consumer shift to online shopping.

Primarily through its retail website - markselectrical.co.uk - the Company offers over 3,000 products from over fifty brands across its main product categories, which include Cooking, Refrigeration, Washers & Dryers, Dishwashers and Audio-Visual. These products are sourced from UK distributors of the brands, with whom the Group maintains strong and direct relationships. Delivery to customers is operated by its own skilled team of delivery drivers in its owned and branded vehicles, who are also able to offer installation and recycling services.

In the year to 31 March 2021 ("FY2021") revenue grew to GBP56 million, up 78% against the previous financial year, while EBITDA increased to GBP7.70 million, at a 13.8% EBITDA margin. The Group has made a strong start to its current financial year to 31 March 2022 ("FY2022"), with revenue growth of 78% in H1 FY2022, versus 47% growth in H1 FY2021. ..."

[blondviking] 05/11/2021 10:58

why the fall today?

[ariane] 09/10/2009 06:33

PRESS RELEASE: Dose-Finding Phase IIb Study Started In Patients With Multiple Sclerosis - Actelion/Roche S1P1 Alliance Achieves (Actelion Ltd)





Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
=---------------------------------------------------------------------
=-------------




ALLSCHWIL, SWITZERLAND - 09 October 2009 - Actelion Ltd (SIX: ATLN)
announced today that the selective S1P1 receptor agonist ACT-128800/
RG3477 has achieved an important clinical milestone. Actelion's
first-in-class selective S1P1 (Sphingosine-1-phosphate) receptor
agonist has entered into a Phase IIb dose-finding study in patients
suffering from multiple sclerosis. This triggers a milestone payment
by Roche to Actelion of USD 20 million.

Guy Braunstein, M.D., Ph.D. and Head of Clinical Development at
Actelion, commented: "Together with our partner Roche, we are
committed to the rapid development of our selective S1P1 receptor
agonist for patients suffering from autoimmune disorders. With the
start of this dose-finding study in patients with multiple sclerosis,
we have made an important step forward."

About the Actelion / Roche alliance
Actelion and Roche entered into an exclusive worldwide collaboration
in July 2006 to jointly develop and commercialize Actelion's
selective S1P1 receptor agonist, an immunomodulator with the
potential for once-a-day oral dosing. The two companies plan to
jointly develop and commercialize this novel compound for multiple
autoimmune disorders. For the current selective S1P1 receptor
agonist, Actelion will fully fund all development activities up to
the end of Phase II for the first two indications. All subsequent
development and commercialization costs will be shared equally
between Roche and Actelion. Both companies will co-promote any
product resulting from this collaboration and will equally share
profit.

This S1P1 collaboration covers both the current selective S1P1
receptor agonist in clinical development, as well as any other
selective S1P1 receptor agonists resulting from Actelion's research
efforts in the field. Actelion received an upfront payment of USD 75
million in July 2006. In the case of future development and approval
milestones being achieved, Actelion will be eligible to receive
further payments of up to USD 535 million for the first compound for
all targeted indications. Further development and approval milestone
payments are due for additional compounds. Roche will pay Actelion
undisclosed royalties on all product sales.

Selective S1P1 receptor agonists
Sphingosine-1-phosphate (S1P) is a phospholipid released by
platelets, mast cells and other cells. It is currently established
[1,2] that S1P stimulates at least five different G-protein coupled
receptors (GPCRs): S1P1,2,3,4, and 5. Activation of these GPCRs
mediates a complex variety of biological responses, such as
lymphocyte migration, endothelial cell proliferation, blood vessel
constriction and heart rate modulation.

Actelion's efforts in the field of selective S1P1 receptor agonists
started in 1999 by focusing on GPCRs found on the endothelium, the
inner lining of blood vessels. The result of these research efforts
is Actelion's orally active selective S1P1 receptor agonist.


###

Notes to the editor

About autoimmune disorders
Autoimmune disorders are diseases caused by the body producing an
immune response against its own tissues. The cause of autoimmune
disorders is unknown. Some of the most common types of autoimmune
disorders include psoriasis, rheumatoid arthritis, multiple
sclerosis, inflammatory bowel disease and rejection of transplanted
organs. These disorders affect millions of people worldwide.

About multiple sclerosis
Multiple sclerosis (MS) is an inflammatory autoimmune disorder of the
central nervous system (CNS) and is the most common cause of
progressive neurological disability in young adults [3,4]. This
chronic demyelinating disease is characterized by heterogeneous
clinical expression, an unpredictable course and a variable
prognosis. MS results from a cascade of events involving an
activation of the immune system, acute focal inflammatory
demyelination, and axonal loss with limited remyelination,
culminating in chronic multifocal sclerotic plaques in brain and
spinal cord. The large variety of symptoms and signs of MS result
from axonal demyelination which leads to the slowing or blockade of
axonal conduction at diverse affected sites of the brain and spinal
cord. Repeated episodes of disease activity may lead to progressive
loss of neurological function.

The incidence of MS is about 7 cases per 100,000 persons per year and
although the etiology of MS is still unknown, the prevalence rate
varies between races and geographical latitudes, ranging from 50-120
per 100,000 [3]. It is widely accepted that it is an immune-mediated,
demyelinating disease precipitated by unknown environmental factors
in genetically susceptible people.

References
1. Huwiler A, Pfeilschifter J. Biochem Pharmacol. 2008 May
15;75(10):1893-900. Review.
2. Rivera J, Proia RL, Olivera A.Nat Rev Immunol. 2008
Oct;8(10):753-63. Review.
3. Compston A, Coles A. Multiple sclerosis. Lancet
2002;359:1221-31.
4. Compston A, Coles A. Multiple sclerosis. Lancet
2008;372:1502-18.

Actelion Ltd
Actelion Ltd is a biopharmaceutical company with its corporate
headquarters in Allschwil/Basel, Switzerland. Actelion's first drug
Tracleer®, an orally available dual endothelin receptor antagonist,
has been approved as a therapy for pulmonary arterial hypertension.
Actelion markets Tracleer® through its own subsidiaries in key
markets worldwide, including the United States (based in South San
Francisco), the European Union, Japan, Canada, Australia and
Switzerland. Actelion, founded in late 1997, is a leading player in
innovative science related to the endothelium - the single layer of
cells separating every blood vessel from the blood stream. Actelion's
over 2000 employees focus on the discovery, development and marketing
of innovative drugs for significant unmet medical needs. Actelion
shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN).


For further information please contact:
Roland Haefeli
Vice President, Head of Investor Relations & Corporate Communications
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
[phone]
[phone]




=-- End of Message ---

Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil
Switzerland

WKN: 936767; ISIN: CH0010532478; Index: SBIOM, SLIFE, SMCI, SMIEXP,
SMIM, SPI, SPIEX;
Listed: Main Market in SIX Swiss Exchange;



Copyright © Hugin AS 2009. All rights reserved

[waldron] 28/9/2009 14:09

Merck To Sell CSL's Flu Vaccine In US Starting Next Year





DOW JONES NEWSWIRES

Merck & Co. (MRK) has agreed to sell CSL Ltd.'s (CSL.AU) seasonal flu vaccine in the U.S. for a six-year period starting next fall, getting the drug giant into that sector.

Terms weren't disclosed for the deal between the companies, who have been vaccine-development partners since 1980.

Afluria was approved by the U.S. Food and Drug Administration two years ago. Merck said with selling the Australian company's vaccine, it will give Merck eight of the 10 vaccines on the recommended list for U.S. adults.

Vaccines have long been one of Merck's primary businesses, which showed strong growth in 2006 and 2007 but has had problems of late amid supply constraints and seen weakened demand. The unit's head will be leaving Nov. 1 ahead of the company's acquisition of Schering-Plough Corp. (SGP).

-By Kevin Kingsbury, Dow Jones Newswires; 212-416-2354; [e-mail]

[waldron] 18/9/2009 07:50

Sanofi-Aventis Completes Acquisition Of Merck Stake In Merial





PARIS -(Dow Jones)- French drug company Sanofi-Aventis SA (SNY) said Friday that it has completed the acquisition of Merck & Co Inc's (MRK) 50% interest in Merial Limited.

MAIN FACTS:

-Sanofi-Aventis acquired Merck's interest in Merial for a cash consideration of $4 billion.

-Formed in 1997, Merial is a leading animal health company that was a 50/50 joint venture between Merck and Sanofi-Aventis and is now a wholly-owned subsidiary of Sanofi-Aventis.

-The acquisition of Merial is expected to be accretive to Sanofi-Aventis' adjusted net income from the first year.

-As per the terms of the agreement signed on July 29, Sanofi-Aventis also has an option, following the closing of the Merck/Schering-Plough merger, to combine the Intervet/Schering-Plough Animal Health business with Merial to form an animal health joint venture that would be equally owned by the new Merck and Sanofi-Aventis. If the option is exercised by Sanofi-Aventis, the formation of the new animal health joint venture would be subject to approval by the relevant competition authorities.

Company Web site: www.sanofi-aventis.com

-By Paris Bureau, Dow Jones Newswires; [phone]; [e-mail]

[waldron] 16/9/2009 11:12

EU Clears Sanofi-Aventis To Buy Merck's Stake In Merial JV





BRUSSELS -(Dow Jones)- The European Commission Wednesday approved French pharmaceuticals firm Sanofi-Aventis SA (SNY) to buy the remaining 50% of its animal health joint venture Merial.

Merial was formed as a 50-50 joint venture with U.S. peer Merck & Co. Inc. (MRK).

-By Carolyn Henson, Dow Jones Newswires; [phone]; [e-mail]

[grupo guitarlumber] 24/7/2009 19:28

UPDATE: Argentina, Brazil Question Swine Flu Vaccine Patents (Merck)





(Updates to include comments and background on Brazil.)

BUENOS AIRES -(Dow Jones)- The presidents of Argentina and Brazil Friday suggested that developing countries be allowed to lift patent rights so they can produce more vaccines to battle the A/H1N1 swine flu epidemic.

In a speech at a regional Mercosur leaders summit in Paraguay, Argentine Cristina Fernandez said changing the status quo "does not mean disavowing the patents law," according to a report by the state news agency Telam.

Brazilian President Luiz Inacio Lula da Silva proposed that leaders discuss breaking the patents law to help contain the epidemic, according to a report by Brazil's state news agency Agencia Brasil.

The news agency also said Brazilian Health Minister Jose Gomes Temporao is negotiating with all vaccine producers to boost the vaccine's availability.

"Brazil is willing to defend the health security of its population," the minister was quoted as saying.

Brazil has been adept in recent years at getting pharmaceutical companies to offer discounts on HIV medication. In 2007 the government issued a compulsory license to break the patent on an anti-retroviral AIDS drug made by U.S. pharmaceutical giant Merck & Co. (MRK).

Argentina's Fernandez, meanwhile, said leaders to work "to lift patent rights and that way allow a vaccine to offer solutions for millions of people."

Fernandez said Argentina and Brazil both have highly developed pharmaceutical industries and should be able to produce vaccine "that wouldn't be free."

"But," Fernandez added, "it's beyond question that we're confronting a situation in which the needs of millions of people cannot be subordinated to economic interests."

Mercosur is a regional customs union founded by Argentina, Brazil, Paraguay and Uruguay.

- By Taos Turner, Dow Jones Newswires; 5411-4103-6728; [e-mail]

[grupo guitarlumber] 23/7/2009 08:17

Merck KGaA Files For Europe Approval For Cladribine





FRANKFURT -(Dow Jones)- Merck KGaA said Thursday it has submitted a marketing authorization application to the European Medicines Agency (EMEA) for Cladribine Tablets, Merck's proprietary investigational oral formulation of cladribine, as a therapy for patients with relapsing-remitting multiple sclerosis (MS).

MAIN FACTS:

-Cladribine Tablets could become the first orally administered disease-modifying therapy available for patients with MS.

-Merck will submit new drug applications for Cladribine tablets in several other countries, including the U.S. in the second quarter.


-Frankfurt Bureau, Dow Jones Newswires; 49-69-29725-500